Literature DB >> 3136430

[In vitro activity of new quinolones against Mycoplasma pathogenic to humans].

H Renaudin1, C Quentin, B de Barbeyrac, C Bebear.   

Abstract

The in vitro activity of new quinolones was evaluated against Mycoplasma pneumoniae (10 strains) and Mycoplasma hominis (approximately equal to 70 strains) by agar dilution, and against Ureaplasma urealyticum (approximately equal to 115 strains) by broth dilution. The static effect of pefloxacin, ofloxacin, ciprofloxacin, enoxacin was investigated for all the strains. Rosoxacin was included in the tests for U. urealyticum and M. hominis. Pefloxacin, ofloxacin, ciprofloxacin and enoxacin were within the same range of sensitivity for M. pneumoniae; the minimal inhibitory concentrations (MICs) of the 10 strains were 1 mg/l for ciprofloxacin, 2 mg/l for pefloxacin, MICs range was (0.05-1 mg/l) for ofloxacin and (0.5-4 mg/l) for enoxacin. Ciprofloxacin was the most active compound against M. hominis; MICs range and mode MICs were respectively in mg/l: (0.1-1) 0.5 for ciprofloxacin, (0.2-2) 0.5 for ofloxacin, (0.5-2) 1 for pefloxacin, (0.5-8) 2 for enoxacin, (2-16) 2 for rosoxacin. Ofloxacin was the most active compound against U. urealyticum; MICs range and mode MICs were respectively in mg/l: (0.2-2) 1 for ofloxacin, (0.1-8) 2 for rosoxacin, (0.5-8) 4 for pefloxacin, (1-16) 4 for ciprofloxacin, (2-32) 8 for enoxacin. No difference could be observed between tetracycline sensitive or resistant strains.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136430

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  9 in total

1.  Peritonitis due to Mycoplasma hominis and Ureaplasma urealyticum in a liver transplant recipient.

Authors:  M Haller; H Forst; G Ruckdeschel; H Denecke; K Peter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

2.  In vitro susceptibility of tetracycline-resistant strains of Ureaplasma urealyticum to newer macrolides and quinolones, and a streptogramin.

Authors:  H Renaudin; C Bébéar; J A Robertson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

3.  Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Authors:  G E Kenny; T M Hooton; M C Roberts; F D Cartwright; J Hoyt
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 5.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors:  K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 7.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 8.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

9.  Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.

Authors:  H Renaudin; C Bébéar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.